How CVS Has Traded Around Earnings
CVS has beaten the official EPS estimate in seven of its last eight reported quarters, an 88% beat rate, with an average earnings surprise of 14%. The four most recent releases show the headline beat is only part of the picture. On May 6, 2026, actual EPS of $2.57 beat the $2.18 estimate by 17.9%, yet the stock rose just 0.58% the next day before climbing 12.95% over the following five sessions. On February 10, 2026, actual EPS of $1.09 beat the $1.00 estimate by 9.0%, leading to a 1.85% next-day gain and a 2.82% five-day drift. October 29, 2025 produced a $1.60 actual versus $1.37 estimate, a 16.8% surprise, but the stock fell 4.85% the next day and 2.54% over five days. On July 31, 2025, actual EPS of $1.81 beat the $1.46 estimate by 24.0%, moving the stock 0.60% the next day and 2.38% over the next five days.
Across the full trailing eight-quarter sample, the average five-day post-earnings move is 3.9%, classified as an upward drift. The directional edge has therefore shown up more reliably in the multi-day window than in the first 24 hours.
Options-Flow Dynamics Into the August 5, 2026 Print
The next CVS earnings release is scheduled for August 5, 2026 before the open, with a consensus EPS estimate of $1.86. The current snapshot shows the stock at $107.74, RSI at 61.4, and the 50-day EMA at $99.75. Heading into the report, implied volatility rises as traders price event risk. Watch at-the-money and near-the-money strikes in expiration cycles that contain the release; an implied-volatility expansion that outpaces the broader Healthcare/Medical - Healthcare Plans tape suggests the market is paying a higher premium for event exposure.
Given the 14% trailing average surprise, the unofficial consensus may be positioned above the published $1.86 estimate when flow anticipates another beat. Call-put skew, open-interest concentration, and block flow in weekly options can reveal whether hedging demand is directional or defensive. With RSI at 61.4, the stock is not at an extreme, but it is extended above the 50-day EMA, which adds context to how dealers may hedge gamma exposure around current strikes.
What a Disciplined Trader Watches
The 88% beat rate and 14% average surprise do not guarantee direction. The first watch is the August 5, 2026 actual EPS versus the $1.86 estimate, followed by the immediate price reaction. The last four next-day moves are 0.58%, 1.85%, -4.85%, and 0.60%, so even a double-digit beat can produce a flat or sharply negative first session. The more consistent historical signal has been the five-day drift: the trailing average is 3.9% up, and the May 2026 quarter added 12.95% over that window after a nearly unchanged first day.
Watch whether the post-report move holds above the 50-day EMA at $99.75, whether RSI extends beyond 61.4 on volume, and whether the five-day drift aligns with the historical upward tendency. The October 2025 example—a 16.8% surprise followed by a -4.85% next-day drop and a -2.54% five-day decline—shows the beat magnitude alone does not dictate price action. For a deeper dive into how institutional positioning may shape the reaction, refer to the full institutional verdict.
Frequently Asked Questions
How often has CVS beaten earnings estimates in the last eight quarters?
CVS has beaten the official EPS estimate in seven of the last eight reported quarters, or 88%, with an average earnings surprise of 14%.
What happened after CVS’s most recent earnings report?
On May 6, 2026, CVS reported actual EPS of $2.57 versus a $2.18 estimate, a 17.9% surprise. The stock moved 0.58% the next day and 12.95% over the following five trading days.
When is CVS’s next earnings report and what is the current consensus?
CVS is scheduled to report on August 5, 2026 before the open. The consensus EPS estimate is $1.86, and the current snapshot shows the stock at $107.74, RSI at 61.4, and the 50-day EMA at $99.75.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-05-06 | $2.57 | $2.18 | +17.9% | +0.58% | +12.95% |
| 2026-02-10 | $1.09 | $1 | +9% | +1.85% | +2.82% |
| 2025-10-29 | $1.6 | $1.37 | +16.8% | -4.85% | -2.54% |
| 2025-07-31 | $1.81 | $1.46 | +24% | +0.6% | +2.38% |
| 2025-05-01 | $2.25 | $1.7 | +32.4% | - | - |
| 2025-02-12 | $1.19 | $0.914 | +30.2% | - | - |
Previous CVS editions
Get the institutional verdict on CVS
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the CVS verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.